Holestatin (Rosuvastatin Calcium)

Holestatin is prescribed to manage elevated cholesterol and to lower the risk of cardiovascular events.

• Primary treatment of hypercholesterolemia (high LDL‑cholesterol) in adults.
• Management of heterozygous familial hypercholesterolemia when diet alone is insufficient.
• Reduction of cardiovascular risk (myocardial infarction, stroke) in patients with established atherosclerotic disease.
• Adjunct therapy for mixed dyslipidemia to lower total cholesterol and triglycerides.
• Secondary prevention of cardiovascular events after myocardial infarction or revascularisation procedures.

• Rosuvastatin calcium competitively inhibits HMG‑CoA reductase, the enzyme that catalyzes the conversion of HMG‑CoA to mevalonate, a key early step in hepatic cholesterol synthesis. By blocking this rate‑limiting step, intracellular cholesterol production falls, prompting up‑regulation of LDL receptors on hepatocyte surfaces, which increases clearance of circulating LDL particles and lowers total and non‑HDL cholesterol levels. The overall effect is a dose‑dependent reduction in serum LDL‑C and modest increases in HDL‑C.

Like other statins, Holestatin may cause adverse reactions that vary in frequency and severity. These events are reported in clinical studies and post‑marketing surveillance.

Common

• Headache – mild to moderate intensity, often transient.
• Muscle pain (myalgia) – aching or soreness without weakness.
• Abdominal discomfort or dyspepsia – bloating, gas, or mild pain.
• Nausea or mild gastrointestinal upset – may include loss of appetite.

Serious

• Rhabdomyolysis – severe muscle breakdown with dark urine and risk of kidney injury.
• Elevated liver enzymes – significant increase in ALT or AST indicating hepatic stress.
• Anaphylactic or severe hypersensitivity reactions – hives, swelling, difficulty breathing.

Before prescribing Holestatin, clinicians evaluate several safety considerations to minimize risk.

• Pregnancy category X – contraindicated in pregnancy; discontinue if pregnancy occurs.
• Breastfeeding – not recommended as it may pass into milk.
• Severe renal impairment – dose adjustment may be required; monitor renal function.
• Active liver disease or unexplained persistent elevations of transaminases – avoid use.
• Concomitant use with strong CYP3A4 inhibitors – may increase rosuvastatin exposure.
• History of myopathy or rhabdomyolysis – use with caution and monitor CK levels.
• Patients over 75 years – consider lower starting dose due to increased sensitivity.

Holestatin can interact with other medicines that affect its metabolism or increase the risk of muscle toxicity.

Avoid

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) – may raise rosuvastatin levels.
• Cyclosporine – markedly increases rosuvastatin exposure and risk of adverse effects.
• Gemfibrozil or other fibrates – heightened risk of rhabdomyolysis.

Use with caution

• Anticoagulants such as warfarin – may enhance anticoagulant effect; monitor INR.
• Antidiabetic agents (e.g., insulin, sulfonylureas) – possible alteration of glucose control.
• Niacin – combined therapy can increase muscle toxicity.